Trial Profile
Phase II Trial of Neutron Radiotherapy With Concurrent Checkpoint Inhibitor Immunotherapy (Pembrolizumab) in Patients With Advanced Urothelial Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Nov 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- 15 Feb 2023 Status changed from recruiting to active, no longer recruiting.
- 15 Dec 2021 Planned End Date changed from 1 Nov 2022 to 1 May 2024.
- 15 Dec 2021 Planned primary completion date changed from 1 Nov 2022 to 1 Nov 2023.